Torsten O. Nielsen, MD, PhD, FRCPC

Torsten O. Nielsen, MD, PhD, FRCPC, a professor of pathology at the University of British Columbia, discusses the difficulties when using Ki67 to measure proliferation in breast cancer.

Ki67 index values are difficult to reproduce between pathologists

Videos

The Challenges of Using Ki67 as a Tool in Breast Cancer

Torsten O. Nielsen, MD, PhD, FRCPC, a professor of pathology at the University of British Columbia, discusses the differences between the PAM50 assay and other approved molecular tests for patients with breast cancer.

Most molecular tests, Nielsen says, are very specific for the patient sets from which they were derived and the type of treatment that patients receive. PAM50 is different because it is a biological test that identifies the intrinsic subtypes of breast cancer, Nielsen says. The PAM50 assay is likely to provide relevant information in different types of breast cancer and in different treatment settings.

Nielsen says there are currently clinical trials that are comparing PAM50 with other tests and applying PAM50 to other types of specimens.

The PAM50 assay was designed around the biology of breast cancer

The PAM50 assay identifies the intrinsic subtypes of breast cancer and is likely to provide relevant information about different types of breast cancer and in different treatment settings

There are currently clinical trials comparing PAM50 to other tests and to apply PAM50 to other types of specimens.

Torsten O. Nielsen discusses the differences between the PAM50 assay and other approved molecular tests for patients with breast cancer.

The Difference Between the PAM50 Assay and Other Molecular Tests

Torsten O. Nielsen, MD, PhD, FRCPC, professor, pathology, University of British Columbia, discusses Ki67 in breast cancer.

In his presentation at the 12th International Congress on the Future of Breast Cancer from July 18-20, 2013, in Huntington Beach, CA, Nielsen discussed the clinical utility of the Ki67 protein in breast cancer.

Ki67 is a convenient immunohistochemical tool for measuring proliferation, which is a critical factor in breast cancer, as well as in other cancers. The nature of the Ki67 protein, with its repeated element, is beneficial for an antigen antibody interaction. This produces the best, cheapest, and most widely available immunohistochemistry to measure proliferation on standard paraffin biopsy specimens.

Ki67 is a convenient immunohistochemical tool for measuring proliferation

The nature of the Ki67 protein is very good for an antigen antibody interaction

Torsten O. Nielsen, MD, PhD, FRCPC | Authors

Articles

The Challenges of Using Ki67 as a Tool in Breast Cancer

The Difference Between the PAM50 Assay and Other Molecular Tests

The Clinical Utility of Ki67 in Breast Cancer